Mubadala, the Abu Dhabi government’s sovereign investment company, has decided to invest about $250 million in Nasdaq-listed Certara, drug development and discovery company via biosimulation, according to a statement from Mubadala on Wednesday.
The Emirati Company said, “This investment is in line with its strategy to employ innovation in meeting clinical and drug needs to serve patients by developing highly effective products at lower costs.”
Details of the Transaction
The statement said that under the agreement with Certara’s partners, including the major shareholder, EQT, Mubadala will acquire 9,615,384 shares at a price of $26 per share from shareholders, as part of a private transaction that is expected to close on August 2, 2021.
EQT will retain its position as a major shareholder in the company after the completion of the transaction.
Certara: It advances drug discovery processes and advances traditional treatment methods using biosimulation software and technology.
Mubadala: Owned by the Abu Dhabi government, it is a huge investment company operating in more than 50 countries around the world, with assets of $243.4 billion, and working in a number of activities including refining, petrochemicals, renewable energy, mining, aviation, technology, agriculture, healthcare, medicine, real estate, and financial investments, according to Mubadala website.